Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Pediatrics
Erschienen in:

01.12.2022 | Pediatric Infectious Disease (M Mitchell and F Zhu, Section Editors)

Optimization of Pediatric Antibiotic Dosing Through Therapeutic Drug Monitoring

verfasst von: Frank Zhu, MD

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Review data and provide recommendations on the optimization of antibiotic dosing in pediatrics through therapeutic drug monitoring (TDM).

Recent findings

Due to physiological alterations, there is growing evidence current weight-based antibiotic dosing regimens are inadequate in obese and critically ill children. Utilization of known PK/PD indices as TDM targets for certain antibiotics (aminoglycosides, vancomycin, β-lactams) in these patients has led to improved clinical results in adults, but pediatric literature remains significantly limited.

Summary

There are significant potential clinical benefits to expansion of TDM from current use (vancomycin, aminoglycosides) to include β-lactams, particularly in the critically ill. The clinical benefits of linezolid and fluoroquinolone TDM remain unclear. There is significant potential for further optimization of TDM based dosing through use of population PK software with Bayesian modeling.
Literatur
1.
•• Roberts J, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27–36. Provides an excellent review of TDM of multiple antimicrobial agents.
2.
Barker CIS, et al. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child. 2018;103(7):695–702.
3.
•• Abdulla A, et al. Model-informed precision dosing of antibiotics in pediatric patients: a narrative review. Front Pediatr. 2021;9:624639. Excellent review of the increasing use of pediatric population PK modeling and effectiveness in optimization of dosing/TDM.
4.
Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266–83.CrossRef
5.
Gritz EC, Bhandari V. The human neonatal gut microbiome: a brief review. Front Pediatr. 2015;3:17.
6.
Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm. 2019;76(19):1472–80.CrossRef
7.
Cies JJ, et al. Beta-lactam therapeutic drug management in the PICU. Crit Care Med. 2018;46(2):272–9.CrossRef
8.
Bernier SP, Surette MG. Concentration-dependent activity of antibiotics in natural environments. Front Microbiol. 2013;4:20.CrossRef
9.
Jumbe N, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112(2):275–85.CrossRef
10.
Barcelo-Vidal J, Rodriguez-Garcia E, Grau S. Extremely high levels of vancomycin can cause severe renal toxicity. Infect Drug Resist. 2018;11:1027–30.CrossRef
11.
Imani S, et al. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891–7.CrossRef
12.
Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10.CrossRef
13.
Rodriguez W, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics. 2008;121(3):530–9.CrossRef
14.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51; quiz 859.
15.
Zuppa AF, Barrett JS. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am. 2008;55(3):735–55, xii.
16.
• Roberts JA, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–83. Description of inadequate β-lactam fT > MIC in critically ill adults resulted in worse clinical outcomes.
17.
Abdul-Aziz MH, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016;71(1):196–207.CrossRef
18.
Cheng V, et al. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(Suppl 5):S629–41.CrossRef
19.
Wells JC, et al. Body composition in normal weight, overweight and obese children: matched case-control analyses of total and regional tissue masses, and body composition trends in relation to relative weight. Int J Obes (Lond). 2006;30(10):1506–13.CrossRef
20.
Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634–49.CrossRef
21.
Harskamp-van Ginkel MW, et al. Drug dosing and pharmacokinetics in children with obesity: a systematic review. JAMA Pediatr. 2015;169(7):678–85.CrossRef
22.
Hales CM, et al. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. 2017;288:1–8.
23.
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.CrossRef
24.
Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol. 1999;47(6):637–43.CrossRef
25.
Rea RS, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674–81.CrossRef
26.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10; quiz 11–2.
27.
• van Lent-Evers NA, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21(1):63–73. Demonstrated the clinical benefits of active TDM of aminoglycosides utilizing an individualized dosing regimen via model-based PK dosing.
28.
Lim WXS, et al. A retrospective review of the efficiency of first-dose therapeutic drug monitoring of gentamicin, amikacin, and vancomycin in the pediatric population. J Clin Pharmacol. 2020;60(1):7–15.CrossRef
29.
Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795–805.CrossRef
30.
Moise-Broder PA, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–42.CrossRef
31.
Holmes NE, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.CrossRef
32.
•• Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. Most recent IDSA guidelines for TDM of vancomycin in MRSA infections.
33.
• Al-Sulaiti FK, et al. Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial. Eur J Drug Metab Pharmacokinet. 2019;44(5):639–652. Demonstrated the benefits of peak-trough-based vancomycin dosing vs trough-based dosing alone.
34.
Kishk OA, et al. Vancomycin AUC/MIC and corresponding troughs in a pediatric population. J Pediatr Pharmacol Ther. 2017;22(1):41–7.
35.
• Le J, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155–63. Demonstrated that lower vancomycin troughs in pediatrics were associated with adequate AUC0–24/MIC.
36.
Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077–9.CrossRef
37.
Rhodin MM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.CrossRef
38.
Zhao W, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449–53.CrossRef
39.
Bush K, Bradford PA. Beta-lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8).
40.
Lodise TP, et al. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320–32.CrossRef
41.
Guilhaumou R, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d’Anesthesie et Reanimation-SFAR). Crit Care. 2019;23(1):104.CrossRef
42.
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31(4):345–51.CrossRef
43.
Abdul-Aziz MH, et al. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36(1):136–53.CrossRef
44.
De Waele JJ, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380–7.CrossRef
45.
Scharf C, et al. The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. J Intensive Care. 2020;8(1):86.CrossRef
46.
Marsot A. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children? J Pharm Pharm Sci. 2020;23:470–85.CrossRef
47.
•• Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of beta-lactam antibiotics. Pharmacotherapy. 2021;41(2):220–233. Excellent overview of utilization/implementation of TDM of β-lactam antibiotics.
48.
Roberts JA, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.CrossRef
49.
Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10–22.CrossRef
50.
van den Elsen SH, et al. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open. 2020;10(6):e035350.CrossRef
51.
Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121(4):303–8.CrossRef
52.
• Galar A, et al. Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. Antimicrob Agents Chemother. 2017;61(10). Overview of linezolid TDM that found signficant fluctuaion in levels without correlation with adverse events, mortality, or poor outcome.
53.
Bolhuis MS, et al. Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis. 2018;67(suppl_3):S327-S335.
54.
• Li SC, et al. Population pharmacokinetics and dosing optimization of linezolid in pediatric patients. Antimicrob Agents Chemother. 2019;63(4). Overview which found significant possibility of underdoseing children with linezolid with MIC ≥ 2.
55.
Rao GG, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83–92.CrossRef
56.
Rayner CR, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–23.CrossRef
57.
Alsultan A. Determining therapeutic trough ranges for linezolid. Saudi Pharm J. 2019;27(8):1061–3.CrossRef
58.
Holford N. Pharmacodynamic principles and target concentration intervention. Transl Clin Pharmacol. 2018;26(4):150–4.CrossRef
59.
Leroux S, et al. Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates. Antimicrob Agents Chemother. 2016;60(4):2039–42.CrossRef
Metadaten
Titel
Optimization of Pediatric Antibiotic Dosing Through Therapeutic Drug Monitoring
verfasst von
Frank Zhu, MD
Publikationsdatum
01.12.2022
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Pediatrics / Ausgabe 4/2022
Elektronische ISSN: 2198-6088
DOI
https://doi.org/10.1007/s40746-022-00259-6

Weitere Artikel der Ausgabe 4/2022

Impact of Technologic Innovation and COVID-19 Pandemic on Pediatric Cardiology Telehealth

  • Cardiology/CT Surgery (K Gist, Section Editor)

Cardiac Arrest in Pediatric Cardiac ICUs: Prevention Comes First

  • Cardiology/CT Surgery (K Gist, Section Editor)

Point-of-Care Ultrasound-Guided Procedures in the Pediatric Cardiac Intensive Care Unit

  • Cardiology/CT Surgery (K Gist, Section Editor)

Pediatric Overactive Bladder and the Role of Sacral Neuromodulation

  • Pediatric Urology (BA VanderBrink and RP Pramod, Section Editors)

Pediatric Nausea—a Review of Current Management

  • Pediatric Gastroenterology (SA Saeed and E Mezoff, Section Editors)

Poor Weight Gain

  • Pediatric Gastroenterology (SA Saeed and E Mezoff, Section Editors)

Kompaktes Leitlinien-Wissen Pädiatrie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Pädiatrie

Weniger Bargeld, weniger Erstickungsnotfälle?

Dadurch, dass immer seltener mit Bargeld gezahlt wird, könnte die Rate an Erstickungsnotfällen bei Kindern zurückgehen. Dieser Hypothese ist ein britisches Forschungsteam in Klinikdaten aus den letzten zweieinhalb Jahrzehnten nachgegangen.

Pneumonie ausschließen: Auf das Röntgenbild ist offenbar Verlass

Das Thoraxröntgen ist gemäß Daten aus den USA eine zuverlässige Methode, um bei Kindern in der Notaufnahme rasch eine Lungenentzündung auszuschließen. Zur Vorsicht rät das Ärzteteam jedoch bei bestimmten klinischen Symptomen.

Kawasaki-Syndrom: Kein ASS mehr in der Akutphase?

Um Kinder mit Kawasaki-Syndrom vor entzündlich bedingten Veränderungen der Koronarien zu bewahren, werden sie in der Akutphase mit intravenösen Immunglobulinen und hochdosierter Acetylsalicylsäure (ASS) behandelt. Neuesten Daten zufolge könnte womöglich auf ASS verzichtet werden.

Neurologische Entwicklung von Kindern: Welchen Einfluss hat Stillen?

Stillen bringt zahlreiche gesundheitliche Vorteile mit sich. Ob dazu auch ein niedrigeres Risiko für Entwicklungsverzögerungen und -störungen gehört, hat nun eine israelische Studie untersucht.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise